I-Mab gets new CEO after long search. Sale of the company coming next?
The drug developer filled an 18-month-long vacuum in its top position by appointing an industry veteran with a history of deal-making as its new CEO Key Takeaways: I-Mab has appointed…
Recent Articles
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK - Mao Geping’s Hong Kong IPO gets lift from regulatory nod
-
DouYu swims away from livestreaming in search of fresher waters
DOYU.US
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
